Callan Family Office LLC Invests $1.12 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Callan Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 1,569 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $39,000. Valley Wealth Managers Inc. bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. Finally, Larson Financial Group LLC grew its position in Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 28 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $707.51 on Friday. The business’s 50-day moving average is $696.12 and its 200 day moving average is $851.05. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a market capitalization of $77.35 billion, a P/E ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

Several research firms have weighed in on REGN. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. TD Cowen cut their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Finally, Bank of America reiterated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.